3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Triple Negative Breast Neoplasms
1
Rheumatoid Arthritis, Systemic Juvenile
1
Rectal Neoplasms
1
Periodic Fevers Syndrome
1
Neoplasms
1
Mevalonate Kinase Deficiency
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Melanoma
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Cryopyrin-Associated Periodic Syndromes
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Ductal
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Arthritis, Juvenile
1
Arthralgia
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
Interventions
Ipilimumab
114
pembrolizumab
95
Nivolumab
91
aldesleukin
86
Interleukin-2
57
Cyclophosphamide
54
Dacarbazine
52
Vemurafenib
39
trametinib
37
Temozolomide
37
incomplete Freund's adjuvant
35
fludarabine phosphate
35
sargramostim
32
dabrafenib
32
fludarabine
26
Bevacizumab
26
Paclitaxel
22
MART-1 Antigen
21
Granulocyte-Macrophage Colony-Stimulating Factor
21
montanide ISA 51
20
Interferon-alpha
20
Cisplatin
20
Carboplatin
19
Sorafenib
18
Introns
17
Biopsy
17
cobimetinib
16
Radiosurgery
16
atezolizumab
15
Radiotherapy
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Melanoma
×
canakinumab
×
Clear all
NCT03484923
2024-06-18
PLATforM
Novartis
Phase 2
Completed
196 enrolled
22 charts